Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other neoplasm 1

Conditions

Lung Neoplasms 2Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Iloprost × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

NCT02784899 2018-06-20

Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation

Yonsei University

Phase NA Completed
40 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡